Information for Patients and Physicians

Autoimmune diseases arise from an overactive immune response, whereby the body attacks its own healthy cells. Many therapies for autoimmune diseases rely on suppressing the immune system to prevent further damage to normal tissues, but have the unwanted side effect of making the patient more susceptible to infection or cancer.

AUTOIMMUNE DISEASE CLINICAL TRIAL
SGN-70 phase I trial

Single-agent dose-escalation trial assessing the safety, tolerability and pharmacokinetics of SGN-70 in autoimmune disease patients
This clinical trial is being conducted in Switzerland.

Privacy Policy  |  Legal Notice